`
`
`Paper No. _____
`Filed: July 9, 2018
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`ANACOR PHARMACEUTICALS, INC.,
`Patent Owner.
`_____________________________
`
`Case IPR2018-01359
`Patent 9,566,289
`_____________________________
`
`
`MYLAN PHARMACEUTICALS INC.’S UPDATED MANDATORY
`NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2018-01359
`Patent 9,566,289
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`
`in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”),
`
`hereby submits the following updated notices in connection with the petition for
`
`inter partes review of U.S. Patent No. 9,566,289, Case IPR2018-01359.
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Revised
`
`The following real parties-in-interest are identified: Mylan Pharmaceuticals
`
`Inc., which is the Petitioner in this matter and a wholly owned subsidiary of Mylan
`
`Inc.; Mylan Inc., which is an indirectly wholly owned subsidiary of Mylan N.V.;
`
`and, in an abundance of caution, Mylan N.V. Also in an abundance of caution,
`
`Mylan further identifies DPT Laboratories Ltd., which is an indirectly wholly
`
`owned subsidiary of Mylan, Inc.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Unchanged
`
`C. Lead and Back-up Counsel - Unchanged
`
`D. Electronic Service – Unchanged
`
`
`
`
`Date: July 9, 2018
`
`
`
`Respectfully submitted,
`
`
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`
`
`-2-
`
`
`
`Case IPR2018-01359
`Patent 9,566,289
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that the foregoing Mylan Pharmaceuticals Inc.’s
`
`Updated Mandatory Notices Under 37 C.F.R. § 42.8 was served on July 9, 2018,
`
`on the Patent Owner at the correspondence address of the Patent Owner as follows:
`
`MORGAN, LEWIS & BOCKIUS LLP (SF)
`Attn: Todd Esker
`One Market, Spear Street Tower, Suite 2800
`San Francisco CA 94105
`
`
`and that additional copies have been delivered to the address of the patent
`
`owner according to the assignments of record at the USPTO at:
`
`ANACOR PHARMACEUTICALS, INC.
`Attn: Ryan Walsh, Vice-President & Chief IP counsel
`1020 East Meadow Circle
`Palo Alto, CA 94303
`
`and to additional counsel at the following address:
`
`Williams & Connolly LLP
`Attn: Aaron Maurer and David Berl
`725 Twelfth Street, N.W.
`Washington, DC 20005
`
`
`
`-3-
`
`
`
`Case IPR2018-01359
`Patent 9,566,289
`And to counsel for Petitioner FlatWing Pharmaceuticals LLC in IPR2018-
`
`00169, as follows:
`
`Husch Blackwell, LLP
`Attn: Philip D. Segrest, Jr.
`120 South Riverside Plaza
`Suite 2200
`Chicago, IL 60606
`
`
`
`
`
`
`
`
`
`Date: July 9, 2018
`
`
`
`
`Respectfully submitted,
`
`
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`-4-
`
`